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AbstrACt
Introduction The provision of healthcare for patients with 
inflammatory arthritis occurs in the context of somewhat 
conflicting targets, values and drivers. Therefore, there is 
a need for introducing ‘value-based healthcare’ defined as 
the value of patient relevant health outcomes in relation to 
costs. This term is a central part of tomorrow’s healthcare 
sector, especially for rheumatic diseases, yet the transition 
is a huge challenge, as it will impact the development, 
delivery and assessment of healthcare.
Aims The aim of this study is to compare medical and 
patient evaluated impact of the traditional settlement and 
financing production (DAGS) controlled healthcare setting 
with a value-based and patient-centred adjunctive to 
standard care.
Methods and analysis Patients with inflammatory 
arthritis receiving treatment in routine care at the 
outpatient clinics in the Capital Region of Denmark will 
prospectively and consecutively be enrolled in a Non-
Intervention-Study framework providing a pragmatic 
value-based management model. A Danish reference 
cohort, used for comparison will be collected as part of 
routine clinical care. The enrolment period will be from 1 
June 2018 until 31December 2023. Baseline and follow-
up visits will be according to routine clinical care. Registry 
data will be obtained directly from patients and include 
personal, clinical and outcomes information. The study 
results will be reported in accordance with the STROBE 
statement.
Ethics and dissemination The study has been notified 
to the Danish Data Protection Agency and granted 
authorisation for the period June 2018 to January 2025 
(pending). Informed consent will be obtained from all 
patients before enrolment in the study. The study is 
approved by the ethics committee, Capital Region of 
Denmark (H-18013158). Results of the study will be 
disseminated through publication in international peer-
reviewed journals.
IntroduCtIon  
Inflammatory arthritides are heteroge-
neous diseases with a wide clinical spectrum 
and diverse outcomes.1 Disease modifying 
strengths and limitations of this study
 ► The protocol describes a novel pragmatic val-
ue-based management model used in real-life set-
tings, that can evaluate and validate agreement of 
the patient identified values with patient perception 
of health, well-being and quality of life, and results 
are expected to delivery of healthcare at the right 
time and with optimal use of healthcare resources.
 ► The study will hopefully identify patient characteristics 
that contribute to a poor medical prognosis (including 
loss of functioning) in patients with inflammatory ar-
thritis that might guide future intervention matching 
(pharmacological and non-pharmacological) and de-
livery of stratified interventions based on a prognostic 
classification.
 ► Although inflammatory arthritis care in outpatient clin-
ics forms the basis of this protocol, the focus could be 
modified for application to other healthcare services, 
particularly for community-based treatments and/or 
treatment of other long-term conditions.
 ► Including only inflammatory arthritis may hamper 
the external validity to other disease areas.
 ► The open study design might introduce bias con-
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antirheumatic drugs (DMARDs) including biological 
treatments have improved the management of inflam-
matory arthritis substantially during the last decades.2 
Nevertheless, only around half of the patients experience 
remission and/or low disease activity to these drugs in 
routine care.3
A look into the future of healthcare shows several chal-
lenges ahead and also great opportunities. Healthcare 
systems around the world must accommodate and adjust 
to simultaneous developments in demographics, climatic 
changes, changing nutritional demands and increased 
nutritional understanding, citizens’ expectations, techno-
logical and scientific advancement and rises in chronic 
non-communicable musculoskeletal and associated 
diseases at pandemic proportions.
Increasing expectations, an ageing population and 
novel treatment options are driving healthcare related 
costs to increase at a faster rate than the expansion in 
the Gross Domestic Product in most high-income coun-
tries.4 As a result, healthcare systems across the world 
are challenged by a need to rationalise resources and to 
improve efficacy as well as effectiveness within the health-
care sector.5
The development of the healthcare sector occurs in 
the context of somewhat conflicting targets, values and 
drivers. Nevertheless, the principal focus for strategies 
describing this development denotes a need to intro-
duce ‘value-based healthcare’ defined as the value of 
patient relevant health outcomes in relation to costs. 
This term is a central part of tomorrow’s healthcare 
sector, yet the transition is a huge challenge, as it will 
impact the development, delivery and assessment of 
healthcare.6
Another societal trend is a demand for a more individ-
ualised approach to healthcare. Advances within sciences 
and clinical healthcare are essential for the development 
of personalised medicine, but in order to fully capitalise 
on these improvements, there is a need to incorporate 
qualitative knowledge about the individual’s everyday life. 
People are distinguishable by their biological variability 
and in terms of how disease affects their lives and how 
individualities affect disease management.7 This is partic-
ularly important in the context of patients having to live 
with lifelong chronic musculoskeletal diseases, often asso-
ciated to other comorbidities.
Technological advances and the data revolution are 
already transforming the healthcare landscape. First of 
all, it is already possible to apply home-based devices and 
apps to facilitate improvements in people’s health, and 
numerous wearable activity trackers and other gadgets 
connected to the cloud are widely used for health-related 
purposes. Second, health-related information is currently 
being captured via national quality databases, registries 
and electronic healthcare record systems, and this infor-
mation is gradually becoming more accessible for citizens 
and healthcare professionals (HCPs) via online portals. 
Third, current evidence supports that online tools can 
in fact improve biomarkers, lifestyle characteristics 
including nutrition as well as patients’ competencies in 
coping with tackling their disease.8–10
rationale and theoretical considerations
In inflammatory arthritis, we postulate that value can be 
assessed from a medical, patient-centred and/or a soci-
etal perspective.11–13 Medical value is the benefit obtained 
from controlling a disease and related conditions (asso-
ciated conditions and comorbidities) by treating these to 
specified targets. Patient-centred value concerns patients’ 
contextual experiences arising from intrapersonal and 
social interactions (interpersonal) in relation to their 
health and well-being and will in the current study be 
addressed through individual goal identifying question-
naires. The International Classification of Functioning, 
Disability and Health (ICF) will be applied as the theoret-
ical measurement framework and data structured within 
the body domain (body structures and functions), activity 
domain (execution of tasks), domain of participation 
(involvement in life situations) and contextual factors 
(personal and environmental factors)14 to support the 
patient-centred value approach. Societal values comprise 
both direct and indirect costs for society, in terms of 
usage of healthcare resources as well as economic issues 
related to loss of employment and/or early retirement 
in relation to inflammatory arthritis.12 The first two are 
pivotal for the well-being of the patients with inflamma-
tory arthritis and the latter is critical for ensuring optimal 
usage of resources and costs in society. This study recog-
nises that value can, and must, be defined by including 
and combining all three value perspectives as in ‘the value 
pyramid’ depicted below (figure 1). There is a potential 
positive and negative interaction between the two bottom 
layers. Together patient-centred value and medical value 
may create societal value in terms of increased work ability 
and diminished healthcare and allowance costs. Societal 
inequity in turn generates poor health and diminished 
personal value. Kinetics and impact of interventions 
(positive or negative) are presumably almost instant 
Figure 1 The value pyramid in inflammatory disease 
management. Treating patients with inflammatory arthritis to 
target is the backbone in creating value. However, individual 
patient-identified concerns, barriers or problems should be 
defined by patients and be regarded as adjunctive targets to 
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in the lower levels of the pyramid; however, the feed-
back between societal value and patient-centred and/or 
medical value is much more tardive and takes years to 
impact.
Incomplete awareness of underlying value creating 
mechanisms in inflammatory arthritis may influence the 
assessment and management of patients with arthritis 
in several ways. This may lead to misinterpretation of 
composite disease outcome measures, which could be 
driven by interpersonal and intrapersonal contextual 
factors that could increase the risk of overtreatment of 
conventional synthetic DMARD (csDMARD) and biolog-
ical DMARD (bDMARD) treatments as well as insufficient 
non-pharmacological patient management and subse-
quent waste of resources.
Research on global patient assessments in inflamma-
tory arthritis has been performed within several domains 
that are relevant to understand the impact of disease on 
patients’ lives, comprising, for example, disease activity, 
fatigue and work ability/productivity.15–17 In addition, 
overall functioning and health is a relevant outcome in 
studies and clinical care. However, limited research has 
been done in inflammatory arthritis on patient global 
assessment for overall functioning, health and value. The 
terminology used for such constructs varies from ‘general 
health’ and ‘well-being’ to’ quality of life’ (QoL) or 
‘health-related quality of life’. Also, terms such as ‘happi-
ness’ and ‘life satisfaction’ have been introduced.18 19
In its purest meaning, ‘health’ refers to the absence 
of disease, but in the broad definition of 1948 from the 
WHO, ‘health’ refers to overall physical, mental and social 
well-being.20 A tentative definition of the construct ‘well-
being’ proposed that it is ‘an umbrella term for different 
valuations that people make regarding their lives, the 
events happening to them, their bodies and minds and 
the circumstances in which they live’.21 For QoL, several 
descriptions can be found in the literature, but usually 
they contain elements of a person’s physical, material, 
social and emotional status, while often emphasising 
the personal appraisal or satisfaction related to these 
aspects.22 23 More recently, the WHO concluded that the 
term ‘well-being’ in the 1948 definition was confusing 
and clarified that ‘functioning (and health)’ and ‘quality 
of life’ are interrelated but not interchangeable.24 While 
‘functioning (and health)’ refers to the objective perfor-
mance (either observed or self-reported), QoL refers to 
the subjects’ satisfaction about one’s performance.
The aims of this study are to (1) compare medical and 
patient evaluated impact of the traditional settlement 
and financing production (DAGS) controlled healthcare 
setting with a value-based and patient-centred adjunctive 
to standard care; (2) identify patient characteristics that 
contribute to a poor medical prognosis (including loss of 
functioning) in patients with inflammatory arthritis that 
might guide future intervention matching (pharmacolog-
ical and non-pharmacological) and delivery of stratified 
interventions based on a prognostic classification;25 (3) 
evaluate and validate agreement of the patient identified 
values with patient perception of health, well-being and 
QoL; (4) iteratively improve this pragmatic value-based 
management model (further elaborated below); (5) study 
societal value (health economics) as long-term outcomes 
of implementing the present pragmatic value-based 
management to patients with inflammatory arthritis, 
when delivered in real-world clinical practice to a hetero-
geneous patient population as compared with traditional 
DAGS-controlled healthcare.
In summary, there is a need to explore and to better 
understand solutions that can address the healthcare 
sectors tasks within the areas of value-based healthcare, 
specifically within the domains of medical, patient-cen-
tred and societal value. The ambitions are tightly coupled 
and to succeed with this challenging endeavour to exploit 
the full potential of each area, it will be necessary to 
address them in a coordinated manner.
MEthods And AnAlysIs
Value-based management setting
Since 1 January 2018 and until end of 2020, the outpa-
tient clinics at departments of Rheumatology involved in 
this study (Copenhagen University Hospitals, Glostrup 
and Gentofte) have been relieved of the DAGS-produc-
tion reimbursement management. Instead, the sites have 
been given the opportunity to develop a value-based 
healthcare management system within fixed budgets, the 
latter defined as a lump-sum of the current budget given 
the previous 3 years and adjusted for inflation, without 
requiring certain amount of DAGS to earn the planned 
budget.
The management model will be designed and reit-
erated with assistance from all stakeholders including 
patient research partners and HCPs according to ‘The 
Parker Model’ a qualitative 3-step approach.26
Management team
In order to meet the objectives of this study, it is important 
for all partners to work successfully together. To fulfil 
this, it is important to provide this collaborative effort 
with an efficient management structure to make sure 
that the coherent nature of the project remains stable for 
the entire duration of the project and ensure timely and 
competent planning and conduction of the study.
The project management team consists of the Spon-
sor-Investigator, Dr Tanja Schjødt Jørgensen who is 
responsible for the execution of the project, the Prin-
cipal Investigator Lars Erik Kristensen who is respon-
sible for the overall scientific planning of the project 
and Chief Administrator Henrik Røgind who is respon-
sible for administrative and financial tasks. The tasks of 
the management team in relation to the progress of the 
project are:
 ► Monthly conferences with clinical and scientific staff 
members at the Parker Institute.
 ► Review and management of project progress in rela-
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 ► Coordinate the scientific publications of the project.
 ► Head the dissemination process.
 ► Head the data management team.
 ► Manage financial tasks.
 ► Facilitate audits.
 ► Create awareness of the study in the non-scientific 
communities.
The data collected in the clinical study will on request 
be made available for further exploitation in the research 
community on publication of the main results of the 
studies. The Parker Institute guarantees to ensure future 
data storage, protection and availability.
The value-based healthcare management model 
(figure 2) will integrate the traditional ‘treat to target’ 
approach with a patient identified goal and prioritised 
functional patient education, courses and/or solutions 
toolbox to be offered based on identified needs.
The first part of defining patient value measures 
(through individual patient goal identification) will be 
derived from current patient preference studies.11 12 
These measures will be used to form a core set of outcome 
measures, which will be assessed continuously by all 
patients and to form a dynamic and individualised sets 
of outcomes measures by asking patients to tailor their 
reporting by appraising available outcome measures 
that are of key relevance for them as individuals. The 
process of outcome identification and testing will be 
started in March 2018. Subsequent iterations and cali-
bration of the instrument and value-based healthcare 
plan will be performed yearly throughout the following 
5 years. Furthermore, as part of the routine clinical care, 
participants will undergo an examination programme 
to assess the variables of interest (table 1). During the 
implementation process of this pragmatic value-based 
healthcare model, functional tailored generic educa-
tional courses and/or solutions will be developed; these 
will among other themes consist of interdisciplinary 
educational courses, work coaches, social patient 
platforms and referral to other health professionals, 
for example, occupational and physical therapy. The 
interventions programmed (educational courses and/
or solutions) will be paid for by redistributing resources 
(the lump-sum) as the project is not accountable for 
certain amount of DAGS. Thus, the budget will equal 
the ‘normal’ budget and be compared with a standard 
of care setting both in terms of quantity and quality of 
patient care.
Figure 2 Illustrates the principles of the pragmatic value-based healthcare model. ACR, American College of Rheumatology 
response criteria; CRP, C reactive protein; DAS28, Disease Activity Score 28; EQ-5D, based on the VAS scoring in the five 
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Table 1 Examination and interview at baseline and follow-up (follow-up will be every 6 months)
Demographics and disease-related characteristics (interview) Baseline
Follow-
ups
Sex (M/F), no. (%) X
Age (years) X
Diagnosis (eg, RA, PsA, AS) X
Disease duration (years) X
Smoking (current (average per week)/previous (average per week)/never) X
Alcohol consumption (no. per week) X
Diabetes (y/n) X
Cardiovascular disease (y/n) X
Dyslipidaemia (or treatment for this) (y/n) X
Mental disorder (depression, anxiety) (y/n) X
Medication
   Use of mild analgesics including NSAIDs (days per month) X X
   Cumulated dose of oral prednisolone during the last month (mg) X X
   Medication history (current and previous csDMARDs and bDMARDs) X X
   Interval (days) between study baseline visit and initiation of new treatment X X
   Date for treatment termination of new drug X X
   Reason for withdrawal of treatment during the study period (lack of effect, adverse events, other) X X
Clinical examination
   VAS physician (0–100 mm) X X
   Height (cm) X
   Weight (kg) X
   Swollen joint count (0–28) X X
   Tender joint count (0–28) X X
   Manual tender point examination (no), only scores≥2 are interpreted as a tender point X X
   Spondyloarthritis Research Consortium of Canada enthesitis score (SPARCC) (xx-xx) X X
Patient-reported outcomes (PROs)
   EQ-5D; VAS pain (0–100 mm) X X
   VAS Health (0–100 mm) X X
   VAS Well-being (0–100 mm) X X
   Multi-Dimensional Health Assessment Questionnaire disability index (MD-HAQ, including visual 
analogue scale for pain and global) (0–3)
X X
   PainDETECT Questionnaire (PDQ) X X
   Personal factors and coping X X
   VAS pain (0–100 mm) X X
   VAS global (0–100 mm) X X
   VAS fatigue (0–100 mm) X X
  Patient Prioritised Problem Identification (PPPI) Questionnaire
 ► Symptom interference with pain (0–10).
 ► Symptom interference with fatigue (0–10).
 ► Symptom interference with social participation (0–10).
 ► Symptom interference with working ability (0–10).
 ► Symptom interference with ADL (0–10).
X X
  Transition Questionnaire score (Trans-Q) X X
Imaging and blood sampling as per routine care
ADL, activities of daily living; AS, ankylosing spondylitis; bDMARD, biological DMARD; csDMARD, conventional synthetic DMARD; 
DMARD, disease modifying anti rheumatic drugs; EQ-5D, based on the VAS scoring in the five domains; NSAIDs, Nonsteroidal anti-
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However, the exact nature and extent of these solutions 
are subject to change and will be developed depending 
on demand and results of the current study.
study design
A cohort of patients with inflammatory arthritis receiving 
treatment in routine care at the outpatient clinics at 
Center for Rheumatology and Spine Diseases (VRR), 
Glostrup and Gentofte Hospitals (Capital Region of 
Denmark) will prospectively be enrolled in a Non-Inter-
vention-Study framework providing the pragmatic value-
based management model. A Danish reference cohort, 
used for comparison will be collected as part of routine 
clinical care through the nationwide Danish registry of 
biological therapies (DANBIO).27 All participants will be 
assessed at baseline. The enrolment period will be from 
1 June 2018 until 31December 2023. Follow-up will be 
assessed every 6th month in accordance with routine clin-
ical care.
Participants
Patients with a diagnosis of inflammatory arthritis who 
may be considered for inclusion will be identified by 
doctors and nurses during routine care, according to 
expert clinical opinion of treating specialist, at depart-
ments of Rheumatology in the Capital Region of Denmark 
(Gentofte and Glostrup Hospital locations).
data collection
Registry data will be obtained directly from patients and 
include personal, clinical and outcomes information. 
Data collection at baseline and follow-up visits will be 
based on questionnaires placed in the clinic and data 
exported to a designated research database. Clinical 
data collection at follow-ups will be based on electronic 
questionnaires accessed via DANBIO; a locked online 
it-platform hosted by the Capital Region of Denmark. 
Questionnaires covering patient value identified key 
evaluation and outcome domains will be implemented 
in paper form and subsequently submitted to a research 
database.
Focus group interviews, in which the subjects can 
reflect what constructs (Patient centred Value, Health, 
Well-being and QoL) represent to them, will be catego-
rised into themes by going back and forward between 
answers and the (expanding) list of themes. Themes will 
further be linked to ICF components (body functions, 
activities and participation, environmental factor or 
personal factor) and ICF chapters.14 For each construct, 
the average number of themes identified as well as the 
proportion of themes representing a specific ICF category 
will be calculated for patients and controls separately. An 
ICF category will be considered relevant, when 10% or 
more of all themes within the construct is related to this 
ICF category.
The focus group interviews use the methodology of 
Concept mapping (CM), a formal group process with a 
structured approach used to identify and organise ideas 
on a topic of interest.28 CM is highly effective for the 
development of outcome measures, such as key patient 
considerations.29 In this study, CM will be conducted 
through three to four, full-day, focus groups including 
patients with inflammatory arthritis or until qualitative 
data saturation (defined as the presence of redundancy 
in emerging concepts) is achieved. If data saturation is 
not achieved additional sessions will be run. At the start 
of each focus group, the CM process will be introduced. 
Clustering analysis will be performed on the participant 
statements generated during the focus groups using 
multidimensional scaling (MDS) analysis (CS Global 
MAX; Concept Systems).30 The x and y values from the 
MDS will be used to perform a hierarchical cluster analysis 
dividing the statements into non-overlapping clusters;31 32 
any duplicate statements within the concept maps will be 
removed.29 33 Independent and thematic analysis of the 
reduced statement pool will be performed separately by 
two healthcare specialists, to identify common clusters 
while preserving both the exact wording of the statements 
and the cluster labels assigned to them by patients during 
the workshops. To identify which issues are of most 
importance participants will be asked to rate the impor-
tance of each statement on a 5-point scale, from 1 (‘not 
important’ for people with inflammatory arthritis) to 5 
(‘very important’ for people with inflammatory arthritis).
Patient and public involvement
Collaboration between patients and professionals in 
developing and disseminating research is relatively new. 
Nevertheless, this study follows the EULAR recommen-
dations34 for the inclusion of patient representatives in 
the contemporary scientific process by adhering to eight 
important aspects. Representative healthcare profes-
sionals and patients were involved in all aspects of the 
protocol development to ensure a systematic representa-
tion of the real care processes and identification of real 
issues. 
Results from the current study will be disseminated to 
participants through newsletter(s) in layman terms and 
the Parker Institute website (http:// parkerinst. dk/). 
In order to maximise impact, we will, with the input of 
patient research partners, also communicate our results 
through a number of other scientific and non-scientific 
channels including, but not limited to: (1) presentations 
at relevant congresses; (2) presentations in relevant fora 
and (3) press briefings.
We would like to thank our patient research partners, 
Søren Herlev Jørgensen and Lilian Dalsgaard for taking 
part in the whole process of preparing the current study.
Variables and outcome measures
Clinical examination
HCPs will perform the interview and clinical examina-
tion, consisting of variables shown in table 1.
Patient demographics and patient-reported outcomes
Patient demographics and medication profile will be 








pen: first published as 10.1136/bmjopen-2018-023915 on 23 October 2018. Downloaded from 
7Jørgensen TS, et al. BMJ Open 2018;8:e023915. doi:10.1136/bmjopen-2018-023915
Open access
patient files. Patient-reported outcomes (PROs) will be 
obtained from electronic questionnaires (table 1) acces-
sible from computer touch screens at the study site.35 
Furthermore, Patient Prioritised Problem Identification 
Questionnaires will be recorded in paper formats and 
serve as a tool for patient empowerment. These outcomes 
will be assessed via a prioritised questionnaire (0–10 scale) 
including assessments of pain, fatigue, work/leisure 
activities, function, discomfort, coping and/or anxiety/
depression/stress. The results from these outcomes will 
be used to define the personalised target to treat and will 
then be allocated if necessary to predefined educational 
tools.
Multi-Dimensional Health Assessment Questionnaire 
(MD-HAQ) derived from the HAQ Health Assessment 
Questionnaire, which includes an index of the three 
rheumatoid arthritis (RA) core data set measures (phys-
ical function, pain and global estimate). It consists of 10 
questions addressing eight different areas of functional 
ability and yields a total score between 0 and 3, with a 
higher score representing increasing disability.36 The 
MD-HAQ is useful in all rheumatic diseases by saving 
time, documenting changes in status over long periods 
and by improving rheumatology care and outcomes.
Health and well-being during the last week on a hori-
zontal VAS from 0 (worst) to 100 (best health, well-being, 
respectively). To avoid an influence of task description 
across global, instructions are similarly formulated with 
a single sentence item. No reference to a specific disease 
will be made. Second, a subgroup of participants will be 
asked to indicate whether they consider dissimilarities 
between the constructs to be present (yes/no). Next, they 
will be invited to think about each of the two constructs 
and to write down what they are taking into account when 
scoring themselves (five lines available per construct). 
Finally, a subgroup of subjects will be asked to score the 
three globals a second time after this forced reflection.
The answers to the open question, in which the subjects 
could reflect what the constructs represent to them, will 
be categorised into themes by going back and forward 
between answers and the (expanding) list of themes. 
Themes will be further linked to ICF components (body 
functions, activities and participation, environmental 
factor or personal factor) and ICF chapters.14 For each 
construct, the average number of themes identified as 
well as the proportion of themes representing a specific 
ICF category will be calculated for patients and controls 
separately. An ICF category will be considered relevant, 
when 10% or more of all themes within the construct 
related to this ICF category.
The Transition Questionnaire (Trans-Q) consists of three 
main questions addressing whether there has been an 
improvement, deterioration or no change regarding pain, 
function and overall condition between the two visits.37 38
Exploratory outcomes and response criteria
Response to treatment and care during the study period 
will be assessed by various outcome variables covering 
composite, clinician and individual patient prioritised 
outcome measures and the composite patient value 
measure (table 2). The latter is a weighted average of the 
individual patient prioritised outcome measures based on 
the patient’s own evaluation or relative importance (each 
scale rated 0–10). The composite measures are chosen 
based on their extensive use in inflammatory arthritis trials 
and routine care, respectively. These are described in the 
following section. Clinician and PROs are shown in table 2.
AnAlysIs And stAtIstICs
sample size considerations
Due to the exploratory design, no statistical power calcu-
lation has been performed. The study will enrol consecu-
tively for 17 months, which presumably allows us to recruit 
Table 2 Outcome measures assessed at follow-up baseline
Composite outcomes ACR20/50/70 (at least 20%/50%/70% improvement in ACR response 
criteria)
MDA (% achieving minimal disease activity)
Δ CDAI
Δ DAS28
Clinical outcomes Δ No. of tender and swollen joints
Δ CRP level
Δ Physician’s global assessment (VAS global)
Patient-reported outcomes Δ VAS-fatigue, Δ VAS-pain, pain detect score, Δ Patient VAS-global







ACR, American College of Rheumatology response criteria; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; DAS28, Disease 
Activity Score 28; EQ-5D, based on the VAS scoring in the five domains; HAQ-MD Multi-Dimensional Health Assessment Questionnaire 
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2.500 patients based on the flow in the out-patient clinics 
at Glostrup and Gentofte. A subsequent 5-year follow-up 
period is planned.
descriptive statistics and main analyses
The study results will be reported in accordance with the 
STROBE statement.39 Missing data at follow-up will be 
imputed by a non-responder assumption (applying base-
line observation carried forward technique for contin-
uous data).
Baseline variables will be described for all participants 
and in relevant subgroups. The cohort of patients enrolled 
in the management model will be compared with patients 
being part of routine clinical care and collected in 
DANBIO on means and SD or medians and IQRs will be 
calculated depending on data distribution and compari-
sons will be performed by χ² test for categorical data and 
Mann-Whitney or Kruskal Wallis test for continuous data. 
P<0.05 are considered to be statistically significant. The 
total number of participants with recorded values will be 
reported. Correlations will be explored by Spearman’s 
rank-order correlation.
Achievement of patient, clinician and composite 
response measures will be described for all patients and 
in subgroups (according to, eg, treatment, PRO profile). 
Regression models will be applied to study if pain 
measurements and/or ultrasonic activity have an impact 
on the treatment response measures (table 2). Crude and 
adjusted estimates will be reported.
Long-term (5 and 10 year) income, allowance and 
healthcare cost estimates (both direct and indirect) will 
be calculated and presented for the cohort of patients 
enrolled in the management model and compared with 
patients being part of routine clinical care (DANBIO) 
(see online supplementary file 1).
dIsCussIon
The vision of the current study is closely aligned with 
the healthcare sectors commitment to help patient’s live 
healthier and to ensure high-quality lives.
The described approach will advance the current setup, 
function, performance and evaluation of the healthcare 
sector in a value-based perspective (what’s of importance 
for the patient). Finally, the study’s combined efforts 
within clinical care and science will create an in-depth 
understanding of the implications of a personalised 
value-based healthcare approach.
In the short term, a successful development and evalua-
tion of the study is expected to result in delivery of a prag-
matic value-based management model used in real-life 
settings that provides patients with needed and relevant 
healthcare at the right time and without wasting health-
care resources. As such, the study will put forward a model 
that empowers patients, facilitates healthcare-promoting 
interactions between patients, caregivers and HCPs and 
encourages a more patient-focused partnership aspiring 
to optimise the disease management in a holistic and 
cooperative manner. This model will offer the possi-
bility for management plans to be tailored according to 
the individual patient’s consent, need, aspirations and 
competencies and ensure that the patient, the HCPs and 
other key stakeholders are all engaged in the advance-
ment of our healthcare sector.
EthICs And dIssEMInAtIon
The study has been notified to the Danish Data Protec-
tion Agency and granted authorisation for the period 
June 2018 to January 2025 (pending). Sensitive personal 
data will be pseudonymised and encrypted according 
to regulations stipulated by the Danish Data Protection 
Agency and informed consent will be obtained from all 
patients before enrolment in the study. Patient research 
partners have been involved in the preparation of the 
study protocol. From our point of view, this observational 
study withholds only minimal or no risk of harm, since no 
change of treatment strategies or any invasive examina-
tions is applied. Results of the study will be disseminated 
through publication in international peer-reviewed jour-
nals. With the input of patient research partners, public 
outreach will be performed by layman articles and reports 
at the Parker Institutes’ website.
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